PCSK9 inhibitors for homozygous familial hypercholesterolemia useful but seldom sufficient
File(s)JACC050620-2211_Merged_PDF (1).pdf (332.58 KB)
Accepted version
Author(s)
Thompson, Gilbert R
Type
Journal Article
Date Issued
2020-07-14
Date Acceptance
2020-07-01
Citation
Journal of the American College of Cardiology, 2020, 76 (2), pp.143-145
ISSN
0735-1097
Publisher
Elsevier
Start Page
143
End Page
145
Journal / Book Title
Journal of the American College of Cardiology
Volume
76
Issue
2
Copyright Statement
© 2020 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000553753200002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
alirocumab
apheresis
evolocumab
homozygous FH
lomitapide
PCSK9 inhibitor
OPEN-LABEL
EVOLOCUMAB
ATHEROSCLEROSIS
EFFICACY
THERAPY
SAFETY
Publication Status
Published
Date Publish Online
2020-07-06